2 no-brainer stocks I’d buy in pharma

Royston Wild reveals two pharma stocks with the capability to deliver knockout profits growth.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

There is no shortage of great pharmaceutical stocks that share pickers can tap into. Blue-chips GlaxoSmithKline and AstraZeneca may grab the lion’s share of investor attention, but a quick glance of the FTSE 250 reveals a number of other great drugs stocks I reckon could make you a fortune. Two of these are Dechra Pharmaceuticals (LSE: DPH) and Indivior (LSE: INDV).

The cat’s whiskers

Unlike the Footsie giants mentioned, Dechra has no patent-related problems that could create bottom-line turbulence in the near term and beyond.

City analysts are expecting the giant in the realm of animalcare to keep earnings swelling by double-digit percentages for some time to come. A 10% rise is forecast for the year ending June 2018, with an extra 12% advance estimated for the following period.

Dechra has spent a fortune through shrewd M&A activity in a bid to build its pipeline and bolster its global footprint, and the business has no plans to slow down yet, a promising signal for future earnings.

Just this week it agreed to pay €340m for veterinary care specialists AST Farma and Le Vet to enhance its position in the Netherlands and across Europe, as well as give it a wide generics product portfolio and an enlarged drugs pipeline. Dechra raised £105m via a share placing to help finance the deal, and it followed hot on the heels of the purchase of New Zealand-based distributor RxVet in December.

The drugs market for agricultural and so-called companion animals is increasingly big business. Dechra saw revenues at constant currencies leap 10.5% between July and December and it is easy to see the top line continue to swell as its new products steadily hit the shelves.

The business deals on a forward P/E ratio of 32.5 times but I consider this to be a fitting premium given its dominant position in a fast-growing marketplace.

Brilliant sales prospects

Indivior will have to wait a little longer to generate meaty profits expansion, although this does not diminish my positive take on the addiction specialist.

The business is expected to follow a predicted 20% earnings slide in 2017 with a 23% fall in the current year. But the bottom line is expected to swing into action from next year, starting with a 3% rise in 2018.

The share price plummeted in September as fears over the impact of generic competition on its heroin addiction-battler Suboxone reached fever pitch. But investors have been piling back in with gusto amid the realisation that these concerns looked significantly overcooked.

The market to help those with opioid addiction is of course a huge one, offering the FTSE 250 share plenty of revenue opportunities in the long run. But Indivior has its eye on other prizes too and this month entered into a strategic agreement with Switzerland’s Addex Pharma to develop treatments for alcohol and cocaine addicts.

The British firm, which paid £5m upfront and will invest in research over the next two years, said that its partner has the “most advanced science” in the realm of GABAB positive allosteric modulators to combat addiction in these areas. The deal could possibly open the door to spectacular sales growth further down the line.

Indivior may change hands on a slightly-lofty prospective P/E rating of 19.1 times, but I believe its strong position in the field of anti-addiction treatments warrants an expensive rating.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Royston Wild has no position in any of the shares mentioned. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. The Motley Fool UK has recommended AstraZeneca. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Businesswoman calculating finances in an office
Investing Articles

Down 86%, could this FTSE growth stock blow up like the Rolls-Royce share price?

Paul Summers remains bowled over by the progress of the Rolls-Royce share price. Could a similar recovery play out in…

Read more »

Blue NIO sports car in Oslo showroom
Investing Articles

NIO stock has soared over 80% since August! Time to buy?

NIO stock has had a phenomenal run of just a few short weeks. This writer sees room for further growth,…

Read more »

Investing Articles

3 simple moves to try and grow value in an ISA, without putting in more money

Christopher Ruane details a trio of moves he'd make to try and improve his Stocks and Shares ISA valuation without…

Read more »

Investing Articles

My best stock to buy for 2024’s smashing the market! Is there more to come?

It's a case of 'so far, so good' for our writer's pick for the best stock to buy for 2024.…

Read more »

Investing Articles

2 fantastic passive income stocks I’d feel confident going all in on

Diversification's considered crucial to safeguard a portfolio of stocks. But if I could choose only two, it would be these…

Read more »

Investing Articles

Best British growth stocks to consider buying in October

We asked our freelance writers to reveal the top growth stocks they’d buy in October, which included three 'Fire' recs!

Read more »

Investing Articles

What’s the dividend forecast for BT shares? Here’s what the experts say

Have I made a mistake in not buying BT shares for the dividend, even while watching the share price dip…

Read more »

Hand of person putting wood cube block with word VALUE on wooden table
Investing Articles

These might just be the cheapest FTSE 100 shares for me to buy next

There are many ways we can consider which are the best UK shares to buy at any time. I'm seeing…

Read more »